This research, published in the Genes & Diseases journal by a team from Fujian Medical University and Sun Yat-Sen University, conducted a comprehensive bioinformatic and clinical analysis to examine the pan-cancer association between ALK mutation, tumor immunity, and ICB efficacy.
By analyzing clinical data from 2,930 patients across 11 different tumor types treated with immune checkpoint inhibitors, researchers discovered that the presence of ALK mutations is an independent favorable predictor of overall survival. Specifically, ALK mutations decreased the risk of patient death by 31%.
Based on these robust findings, the team developed and validated a nomogram to successfully estimate 12-month and 24-month survival probabilities for patients following the initiation of immunotherapy. Multi-omics analyses further revealed that ALK-mutant tumors exhibit significantly heightened intrinsic immunity, characterized by a higher tumor mutation burden (TMB) and an increase in both non-silent and silent mutation rates.
Moreover, the study deciphered the underlying extrinsic immune mechanisms driven by ALK mutations. Compared to non-mutant tumors, ALK-mutant tumors demonstrated a heavily enriched infiltration of immune cells, higher abundances of neoantigens, and greater T-cell and B-cell receptor (TCR/BCR) diversity. Crucially, the mRNA expression levels of major immune checkpoints, including CTLA-4, PD-1, and PD-L1, alongside various immune-stimulators and chemokines, were significantly upregulated in ALK-mutant tumors.
Remarkably, these findings demonstrate that ALK-mutant tumors function as immunologically "hot" tumors, uniquely primed for robust responses to immune checkpoint inhibitors. While these collective data highlight the crucial role of ALK mutations in shaping a favorable systemic and local immune landscape, additional prospective trials are needed to fully validate these results and explore optimal immunotherapy combination strategies.
In conclusion, treating ALK mutation as a pan-cancer biomarker offers a powerful new strategy to identify patients who will benefit most from immune checkpoint blockade. This profound finding positions ALK mutation screening as an essential tool for personalized clinical decision-making and the development of next-generation cancer immunotherapies.

Reference

Title of Original Paper: Pan-cancer analysis of ALK mutation and its association with tumor immunogenicity and the efficacy of immune checkpoint blockade

Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101701

Funding Information:
The National Natural Science Foundation of China (No. 82373367)
# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4
# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #